Company: INKT
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001193125-25-159014
Chunk: 33

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 33
---
 • |     | the identity of any depositaries, execution or paying agents, transfer agents, registrars or other agents; |

| • |     | the relative ranking and preferences of the preferred stock as to dividend rights and rights upon liquidation, 
 dissolution or winding up of the affairs of the Company; and                                                   |

| • |     | any material limitations on issuance of any class or series of preferred stock ranking senior to or on a parity                 
 with the series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of the Company. |

The preferred stock offered by this prospectus, when issued, will not have, or be subject to, any preemptive or similar rights. 15

DESCRIPTION OF OUR WARRANTS We may issue warrants to purchase our common stock, preferred stock or debt securities in one or more series together with other securities or separately, as described in each applicable prospectus supplement and subject to applicable law. Below is a description of certain general terms and provisions of the warrants that we may offer. Particular terms of the warrants will be described in the applicable warrant agreements and the applicable prospectus supplement for the warrants. The applicable prospectus supplement will contain, where applicable, the following terms of and other information relating to the warrants:

| • |     | the specific designation and aggregate number of, and the price at which we will issue, the warrants; |

| • |     | the currency or currency units in which the offering price, if any, and the exercise price are payable; |

| • |     | the designation, amount and terms of the securities purchasable upon exercise of the warrants; |

| • |     | if applicable, the exercise price for our common stock and the number of common stock to be received upon 
 exercise of the warrants;                                                                                 |

| • |     | if applicable, the exercise price for our preferred stock, the number of preferred stock to be received upon 
 exercise of the warrants, and a description of that series of our preferred stock;                           |

| • |     | if applicable, the exercise price for our debt securities, the amount of our debt securities to be received upon 
 exercise of the warrants, and a description of that series of debt securities;                                   |

| • |     | the date on which the right to exercise the warrants will begin and the date on which that right will expire or,                             
 if the warrants may not be continuously exercised throughout that period, the specific date or dates on which the warrants may be exercised; |

|